Dr. Oscar Yamamoto

Oncology pharmacist · Memorial Sloan Kettering · United States (US) · Oncology

Tier 3STK-0028GoodOwner MSL JWJames Whitfield

Data minimisation

Consent status: Recorded. The name shown may be a pseudonym. Contact details, personal identifiers and remuneration fields are hidden for your role; only scientific-profile fields needed for engagement planning are displayed.

Specialty: Thoracic oncology
Disease interests: SCLC
Scientific interests: Elderly patientsBrain metastases
Engagement preference: Virtual
Advisory boards: 1
Publications: 3
Source system: Veeva CRM
Data quality: Good

Engagement plan

Cadence target for Tier 3: 1 per year (assumption)

Last engaged: 24 May 2026 (114 days ago)
Next planned contact: 24 May 2027
Last 6 months vs target: 100%
1 of 1 expected engagements

Insights from this stakeholder (1)

INS-0023Chemotherapy-free first line
26 May 2026 · Diagnosis and screening
HighOutcome recorded

Engagement history (1)

All engagements including drafts, newest first

Date	Type	Format	MSL	Product	Topics	Insights	Flags	Status
24 May 2026	Investigator meeting	In person	James Whitfield	Vantrexa	Chemotherapy-free first line	1	—	Reviewed	ENG-0071

Timeline

24 May 2026
Investigator meeting
Chemotherapy-free first line

Related stakeholders (6)

Memorial Sloan Kettering

Dr. Zoë Eriksen
Thoracic medical oncologist
Tier 1
Dr. Farah Kimura
Thoracic medical oncologist
Tier 3
Dr. Andrea Abbott
Thoracic medical oncologist
Tier 1
Dr. Zoë Garcia
Academic nephrologist
Tier 1
Dr. Benedikt Dubois
Headache specialist
Tier 3
Dr. Sven Fischer
Allergist
Tier 3